Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort
about
Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, TanzaniaHepatic profile analyses of tipranavir in Phase II and III clinical trialsRisk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.Seroprevalence of HBV and HIV co-infection in children and outcomes following highly active antiretroviral therapy (HAART) in Uyo, South-South NigeriaPredictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study.Transient Elastography for the Detection of Liver Damage in Patients with HIVHIV-related liver disease: ARV drugs, coinfection, and other risk factors.Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection.Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report.Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection.High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort studyCohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort)
P2860
Q27485160-853964CC-6B29-49C3-974D-74DCB39E86BDQ33518011-C7D05937-9752-4A5A-AA5F-EE82678D2D05Q33609481-DFABC08C-CDE3-43C8-8848-C71CE9D4A4AEQ33751609-8C70A410-EA7D-48CE-B6A1-2DDA512D8E83Q34474961-DE2A7C06-AF3D-4A18-9062-D1017B206950Q36073396-1DA0EB50-66FA-472C-A5B6-9E031B7430A0Q37391122-27CEF436-951C-41C6-8E25-9F905F55B13FQ38606313-9A3DB4F1-C3F0-4EB8-BFC4-6C9F56ACC3E4Q39160282-4EA2B791-4074-420D-9D9F-E3F127B64DC3Q39244103-5EB95257-2D4B-4391-B365-93136FD3259DQ56829831-86F2BF4E-38B6-44D6-B593-1A8AE0F69914Q58485602-1D0C28B8-BF12-41C2-BFF0-0D106DD39EE4
P2860
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Incidence and risk factors for ...... he Italian EPOKA-MASTER Cohort
@ast
Incidence and risk factors for ...... he Italian EPOKA-MASTER Cohort
@en
Incidence and risk factors for ...... he Italian EPOKA-MASTER Cohort
@nl
type
label
Incidence and risk factors for ...... he Italian EPOKA-MASTER Cohort
@ast
Incidence and risk factors for ...... he Italian EPOKA-MASTER Cohort
@en
Incidence and risk factors for ...... he Italian EPOKA-MASTER Cohort
@nl
prefLabel
Incidence and risk factors for ...... he Italian EPOKA-MASTER Cohort
@ast
Incidence and risk factors for ...... he Italian EPOKA-MASTER Cohort
@en
Incidence and risk factors for ...... he Italian EPOKA-MASTER Cohort
@nl
P2093
P2860
P50
P921
P356
P1476
Incidence and risk factors for ...... he Italian EPOKA-MASTER Cohort
@en
P2093
Carlo Torti
Daniele Bella
EPOKA-MASTER Study Group
Eugenia Quiros-Roldan
Francesco Mazzotta
Gaetano Filice
Giampiero Carosi
Giovanni Di Perri
Giuseppe Lapadula
Giuseppe Pastore
P2860
P2888
P356
10.1186/1471-2334-5-58
P407
P50
P577
2005-07-14T00:00:00Z
P5875
P6179
1032999185